NCT05335369 (UR-GOAL 2) is a NA clinical trial of UR-GOAL in Acute Myeloid Leukemia, sponsored by University of Rochester.

Who is sponsoring NCT05335369?

NCT05335369 is sponsored by University of Rochester.

What drugs are being tested in NCT05335369?

Interventions in NCT05335369: UR-GOAL.

What condition does NCT05335369 study?

NCT05335369 studies Acute Myeloid Leukemia.

Is NCT05335369 still recruiting?

NCT05335369 is currently completed. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT05335369: UR-GOAL 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists

Completed NA Last updated 9 February 2026

What this trial tests

NA trial testing UR-GOAL in Acute Myeloid Leukemia in 170 participants. Completed in 6 October 2025.

Timeline

17 June 2022

Primary endpoint
7 April 2025

6 October 2025

Quick facts

Lead sponsor	University of Rochester
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	170
Start date	17 June 2022
Primary completion	7 April 2025
Estimated completion	6 October 2025
Sites	1 location across United States

Drugs / interventions tested

UR-GOAL

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

University of Rochester

Who can join

60 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to conduct a pilot randomized trial to evaluate the preliminary efficacy of the UR-GOAL tool in improving SDM and communication between 100 older patients with AML and their oncologists.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Patient-centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: A single-arm pilot study.
LoCastro M, Sanapala C, Wang Y, Jensen-Battaglia M, et al · · 2023 · cited 13× · PMID 36533397 · DOI 10.1002/cam4.5547
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.
Niscola P, Gianfelici V, Catalano G, Giovannini M, et al · · 2024 · cited 10× · PMID 39590121 · DOI 10.3390/curroncol31110490
Adapting a patient-centered communication tool for older patients with acute myeloid leukemia and their oncologist.
Watson E, Sanapala C, Cortes AM, Klepin HD, et al · · 2022 · cited 8× · PMID 35930701 · DOI 10.1182/bloodadvances.2022008041
Patient-oncologist discussion of treatment decisions: Exploring the role of a patient-centered communication tool for older adults with acute myeloid leukemia and their caregivers.
Jensen-Battaglia M, LoCastro M, Oh H, Sanapala C, et al · · 2024 · cited 1× · PMID 38336521 · DOI 10.1016/j.jgo.2024.101716
Challenges in hospice and end-of-life care in the transfusion-dependent patient.
Rodenbach R, Caprio T, Loh KP. · · 2024 · PMID 39644067 · DOI 10.1182/hematology.2024000560

Verify or expand the search:

Other trials of UR-GOAL

Trials testing the same drug.

NCT06697600 — A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers · NA · recruiting

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05335369 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05335369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing